The flu shot for the 2024–2025 season offered moderate protection, reducing outpatient flu visits by roughly 32% to 60% depending on age group and the monitoring network, and cutting hospitalizations by 41% to 78%. Those numbers land in the typical range for flu vaccines, which vary year to year based on how well the vaccine strains match what’s actually circulating. The short answer: the shot helped, especially against severe illness, but it wasn’t a guarantee against getting sick.
How Well the Vaccine Performed This Season
The CDC’s interim estimates for the 2024–2025 season, drawn from four vaccine effectiveness networks tracking patients from October 2024 through February 2025, paint a mixed but broadly positive picture. Among children and teens, the vaccine reduced outpatient flu visits by 32% to 60% and prevented flu-related hospitalizations by 63% to 78%. Among adults, outpatient protection ranged from 36% to 54%, and hospitalization protection came in at 41% to 55%.
The wide ranges reflect the different networks the CDC uses to track effectiveness, each covering different patient populations and regions. But the consistent pattern across all of them is that the vaccine did more to keep people out of the hospital than it did to prevent milder illness. That’s typical. Even in years when the flu shot doesn’t prevent infection entirely, it tends to blunt the severity of symptoms and reduce the risk of dangerous complications like pneumonia.
Which Strains Circulated This Year
The 2024–2025 season was dominated by two influenza A subtypes circulating at nearly equal levels: A(H1N1)pdm09 made up about 53% of subtyped viruses, and A(H3N2) accounted for the remaining 47%. Influenza B stayed low for most of the season, with a slight uptick later on. All identified B viruses belonged to the Victoria lineage. The Yamagata lineage of influenza B hasn’t been detected anywhere in the world since March 2020 and is likely extinct.
This roughly even split between H1N1 and H3N2 is notable because H3N2 is historically the trickier target. It mutates faster than other flu strains, and vaccines tend to perform less effectively against it. Seasons dominated entirely by H3N2 often see lower overall vaccine effectiveness, so the co-circulation of H1N1 likely helped keep the vaccine’s overall numbers from dropping further.
Protection for Older Adults and Children
Flu vaccines typically work best in healthy younger adults and children, and less reliably in people over 65, whose immune systems generate a weaker response to vaccination. This season followed that pattern. For adults 65 and older, outpatient protection ranged from 30% to 41%, and protection against hospitalization was around 31% in one major network. Those numbers are lower than what younger adults and children experienced, but they still represent meaningful risk reduction at a population level. For every 100 older adults who would have been hospitalized without vaccination, roughly 31 avoided that outcome because they were vaccinated.
Children fared better. Protection against hospitalization reached as high as 78% in one monitoring network, making kids one of the groups with the strongest vaccine response this season. Given that children under 5 are among the most vulnerable to severe flu complications, that level of protection carries real weight.
What “Moderate Effectiveness” Actually Means
Numbers like 36% or 54% can feel underwhelming compared to vaccines for diseases like measles, which are over 95% effective. But flu vaccines operate under fundamentally different constraints. The virus changes constantly, and the vaccine has to be reformulated every year based on predictions about which strains will dominate months later. Some years those predictions land closer to the mark than others.
Even at moderate effectiveness levels, the flu vaccine prevents millions of illnesses each season. A 40% reduction in your odds of getting sick is roughly equivalent to cutting your risk nearly in half. And the protection against severe outcomes, including hospitalization and ICU admission, tends to run higher than protection against infection alone. You might still catch the flu after vaccination, but you’re meaningfully less likely to end up in the hospital because of it.
How the Vaccine Is Built Each Year
For the 2025–2026 season, the FDA recommended a trivalent vaccine (three strains) covering an H1N1 virus, an H3N2 virus, and a B/Victoria lineage virus. There are slightly different strain selections for egg-based vaccines versus cell-based and recombinant vaccines, because viruses grown in eggs can pick up small mutations during production that make them less similar to the wild virus. Cell-based and recombinant vaccines avoid that issue, though the CDC has not released comparative effectiveness data between the two manufacturing methods for this specific season.
The 2025–2026 Northern Hemisphere vaccine uses the same composition as the 2025 Southern Hemisphere vaccine. Data from the southern hemisphere’s recent flu season showed that formulation reduced outpatient flu visits by about 50% and hospitalizations by roughly the same margin. Protection was strongest against influenza B viruses (62% for outpatient illness, 78% for hospitalization) and somewhat lower against H3N2 (37% against hospitalization). If the same strains circulate in the Northern Hemisphere, health authorities expect similar levels of protection.
Timing and How Long Protection Takes
Your body needs about two weeks after vaccination to build up enough protective antibodies. That’s why public health agencies recommend getting vaccinated by the end of October, before flu activity typically ramps up in November and December. Getting vaccinated later in the season still helps, especially since flu can circulate well into March or April, but earlier timing gives you the broadest window of coverage.
Protection also wanes over time. Antibody levels start declining a few months after vaccination, which is one reason the vaccine is reformulated and readministered annually rather than given once every few years. For most people, the strongest protection falls within the first three to four months after the shot.